State Street’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

State Street’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-275,605	Closed	-$728K	–	3918
2020 Q1	$728K	Buy	275,605 +60,536	+28%	+$99.3K	﹤0.01%	3372
2019 Q4	$254K	Sell	215,069 -6,199	-3%	-$9.91K	﹤0.01%	3610
2019 Q3	$381K	Buy	221,268 +28,334	+15%	+$86.2K	﹤0.01%	3538
2019 Q2	$915K	Buy	192,934 +77,047	+66%	+$431K	﹤0.01%	3433
2019 Q1	$749K	Buy	115,887 +59,118	+104%	+$309K	﹤0.01%	3393
2018 Q4	$286K	Buy	56,769 +46,569	+457%	+$326K	﹤0.01%	3516
2018 Q3	$87K	Buy	+10,200	New	+$113K	﹤0.01%	3662

State Street's NTGN Position: Q2 2020 in Review

State Street sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 275,605 shares — an estimated $728K sold.

State Street first reported a position in NTGN in Q3 2018 and held it in 7 quarters. The position peaked at $915K in Q2 2019. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

State Street reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
State Street sold 275,605 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $728K.
State Street first reported a position in Neon Therapeutics, Inc. Common Stock in Q3 2018 and held it in 7 quarters.
State Street's Neon Therapeutics, Inc. Common Stock position peaked at $915K in Q2 2019.
0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on State Street's 13F filing for Q2 2020, filed 14 Aug 2020.